HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Core Viewpoint - HOOKIPA Pharma Inc. is set to present updated Phase 2 data for eseba-vec (HB200) in combination with pembrolizumab for treating first-line recurrent/metastatic HPV16-positive head and neck cancer at the upcoming SITC 2024 conference [1][3]. Group 1: Presentation Details - The late-breaking poster presentation will be conducted by Dr. Alan Ho from Memorial Sloan Cancer Center on November 9, 2024, from 9:00 AM to 8:00 PM CDT [2][3]. - The abstract title for the presentation is "Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients" [3]. Group 2: Product Information - Eseba-vec (HB-200) is an investigational immunotherapeutic agent targeting HPV16 positive cancers, specifically for patients with HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma (R/M OPSCC) with a PD-L1 CPS of 20 or higher [4]. - The drug has received Fast Track Designation from the U.S. FDA and PRIME designation from the European Medicines Agency for its potential use in first-line treatment of HPV16+ OPSCC [4]. Group 3: Company Overview - HOOKIPA Pharma Inc. focuses on developing next-generation immunotherapeutics using its proprietary arenavirus platform, aiming to induce robust CD8+ T cells and antibodies to combat cancers and serious infectious diseases [5]. - The company's pipeline includes therapies targeting HPV16+ cancers, KRAS mutated cancers, and partnerships with Gilead for developing treatments for hepatitis B virus and HIV-1 [5].